SEC 13F Intelligence

Managers / Q1 2026

Atle Fund Management AB

CIK 0001381843 · RIDDARGATAN 23A, STOCKHOLM, V7, SE-114 57 · 46 08 440 38 30

Reported Value
$310M
Q1 2026
Positions
39
Filings on Record
19
2019–present window
Filed
May 11, 2026
original filing

Summary

Atle Fund Management AB reported $310M in U.S.-listed holdings across 39 positions for Q1 2026.

Its largest position, LLY, represents 8.7% of the portfolio.

Compared with Q4 2025, the fund opened 4 new positions and exited 4.

Portfolio Metrics

Turnover
+15.5%
vs prior filed quarter
Top-10 Concentration
+45.5%
share of reported value
Largest Position
+8.7%
Eli Lilly
New / Exited
4 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $151MQ4 ’20Q1 ’21: $126MQ2 ’21: $106MQ3 ’21: $67MQ3 ’21Q4 ’21: $71MQ1 ’22: $63MQ2 ’22: $43MQ2 ’22Q3 ’22: $47MQ4 ’22: $52MQ4 ’23: $128MQ4 ’23Q1 ’24: $164MQ2 ’24: $164MQ3 ’24: $213MQ3 ’24Q4 ’24: $211MQ1 ’25: $227MQ2 ’25: $234MQ2 ’25Q3 ’25: $27MQ4 ’25: $313MQ1 ’26: $310MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 90.1%ADR: 5.5%Other: 4.4%
  • Common Stock · 90.1% · $279M
  • ADR · 5.5% · $17M
  • Other · 4.4% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
JNJJOHNSON & JOHNSONNEW+92.4K92.4K+$12M$12M
EWEDWARDS LIFESCIENCES CORPNEW+106.5K106.5K+$8M$8M
TNGXTANGO THERAPEUTICS INCNEW+29.9K29.9K+$4M$4M
SYRESPYRE THERAPEUTICS INCNEW+62.7K62.7K+$3M$3M
DC4DEXCOM INCADDED+544.6K584.3K+$3,574$3M
BCAXBICARA THERAPEUTICS INCADDED+1.06M1.17M+$440,996$2M
RVMDREVOLUTION MEDICINES INCADDED+527.1K617.2K+$2M$9M
CAHCARDINAL HEALTH INCADDED+85.2K108.7K−$54,875$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

39 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYELI LILLY & COhistory →COM8.67%$27M39.7K
2MRKMERCK & CO. INChistory →COM7.40%$23M33.9K
3TMOTHERMO FISHER SCIENTIFIC CORPhistory →COM4.67%$14M23.0K
4ONCBEONE MEDICINES LTD-ADRhistory →SPONSORED ADS3.92%$12M41.7K
5JNJJOHNSON & JOHNSONhistory →COM3.86%$12M92.4K
6BBIOBRIDGEBIO PHARMA INChistory →COM3.84%$12M111.4K
7VRTXVERTEX PHARMACEUTICALS INChistory →COM3.61%$11M23.0K
8ABBVABBVIE INChistory →COM3.35%$10M108.2K
9SYKSTRYKER CORPORATIONhistory →COM3.09%$10M26.8K
10ISRGINTUITIVE SURGICAL INChistory →COM NEW3.05%$9M70.9K
11ISIIONIS PHARMACEUTICALS INChistory →COM3.03%$9M27.9K
12MIRMMIRUM PHARMACEUTICALS INChistory →COM3.03%$9M195.8K
13CVSCVS HEALTH CORPhistory →COM2.99%$9M23.8K
14RVMDREVOLUTION MEDICINES INChistory →COM2.93%$9M617.2K
15BSXBOSTON SCIENTIFIC CORPhistory →COM2.86%$9M40.4K
16AMGNAMGEN INChistory →COM2.81%$9M21.9K
17EWEDWARDS LIFESCIENCES CORPhistory →COM2.67%$8M106.5K
18ALKERMES PLCSHS2.66%$8M242.5K
19INCYINCYTE CORPhistory →COM2.57%$8M50.8K
20NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.54%$8M89.7K
21GILDGILEAD SCIENCES INChistory →COM2.31%$7M48.0K
22KRYSKRYSTAL BIOTECH, INChistory →COM2.19%$7M37.6K
23ABGCENCORA INChistory →COM2.13%$7M23.5K
24IRTCIRHYTHM TECHNOLOGIES INChistory →COM2.02%$6M22.3K
25IM8NINSMED INChistory →COM PAR $.011.92%$6M97.4K
26NEWAMSTERDAM PHARMA CO NVORDINARY SHARES1.78%$6M94.8K
27CELCCELCUITY INChistory →COM1.66%$5M141.3K
28ABVXABIVAX SAhistory →SPONSORED ADS1.54%$5M31.6K
29CAHCARDINAL HEALTH INChistory →COM1.54%$5M108.7K
30IDYAIDEAYA BIOSCIENCES INChistory →COM1.30%$4M31.1K
31TNGXTANGO THERAPEUTICS INChistory →COM1.17%$4M29.9K
32SYRESPYRE THERAPEUTICS INChistory →COM NEW1.13%$3M62.7K
33IRONDISC MEDICINE INChistory →COM1.03%$3M107.3K
34CMPXCOMPASS THERAPEUTICS INCCOM0.99%$3M41.8K
35UNHUNIVERSAL HEALTH SERVICES INCCOM0.90%$3M14.6K
36DC4DEXCOM INCCOM NEW0.85%$3M584.3K
37BCAXBICARA THERAPEUTICS INCCOM0.75%$2M1.17M
38SLNOEURSOLENO THERAPEUTICS INCCOM0.71%$2M90.2K
39PYXSPYXIS ONCOLOGY INCCOMMON STOCK0.52%$2M197.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$310M39May 11, 202613F-HRchanges · EDGAR ↗
Q4 2025$313M39Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$27M38Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$234M37Jul 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$227M37May 5, 202513F-HRchanges · EDGAR ↗
Q4 2024$211M36Feb 4, 202513F-HRchanges · EDGAR ↗
Q3 2024$213M36Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$164M38Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$164M44Apr 25, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M45Jan 30, 202413F-HRchanges · EDGAR ↗
Q4 2022$52M53Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$47M10Oct 21, 202213F-HRchanges · EDGAR ↗
Q2 2022$43M12Jul 8, 202213F-HRchanges · EDGAR ↗
Q1 2022$63M12May 5, 202213F-HRchanges · EDGAR ↗
Q4 2021$71M13Jan 18, 202213F-HRchanges · EDGAR ↗
Q3 2021$67M17Nov 8, 202113F-HRchanges · EDGAR ↗
Q2 2021$106M9Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$126M15Apr 30, 202113F-HRchanges · EDGAR ↗
Q4 2020$151M17Feb 5, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.